No Data
NuCana's NUC-3373 Shows Promise in Cancer Treatment
NuCana Shares Results For Cancer Therapy, Sees Partial Responses In Phase 1b/2 Study
Express News | NuCana Announces Encouraging Initial Data From Phase 1B/2 Modular Study of Nuc-3373 in Combination With Pembrolizumab or Docetaxel
NuCana Announces Encouraging Initial Data From Phase 1b/2 Modular Study of NUC-3373 in Combination With Pembrolizumab or Docetaxel
Truist Financial Sticks to Their Buy Rating for Nucana (NCNA)
Truist Slashes Price Target on NuCana to $20 From $150 Amid Discontinuation of NUC-3373, Keeps Buy Rating
No Data
No Data